tirzepatide vs cagrisema tirzepatide: which next-generation weight loss treatment wins? CagriSema shows substantial weight loss

Geriatric use: There is no information on the use of EGRIFTA WR TM in patients greater than 65 years of age

Lader M

Retatrutide Pharmacokinetics Retatrutide Half-Life: What the Phase 2 Data Actually Shows Retatrutide has a half-life of approximately 6 days, according to the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023)

Effect of physicochemical properties on intranasal nanoparticle transit into murine olfactory epithelium

The demonstration of cardiorenal benefits with SGLT2i in clinical trials both for participants with CKD and type 2 diabetes and for those without [23,24,25] and the updated 2022 KDIGO guidelines recommending SGLT2i as first-line therapy for patients with CKD and type 2 diabetes regardless of glycemic control [6] have likely driven a shift toward their broader use for preventive cardiorenal protection and earlier implementation for patients with type 2 diabetes

Blood tests may be recommended to check for anemia or other indicators of bleeding, particularly in patients with higher risk profiles or those experiencing concerning symptoms during treatment